Symbols / SYRE Stock $69.67 +0.62% Spyre Therapeutics, Inc.
SYRE (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Ratings
Current target
$69.67
Low
$64.00
High
$115.00
Mean
$90.13
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-17 | main | Jones Trading | Buy → Buy | $95 |
| 2026-04-14 | main | Wells Fargo | Overweight → Overweight | $90 |
| 2026-04-14 | main | Wedbush | Outperform → Outperform | $80 |
| 2026-04-14 | main | Baird | Outperform → Outperform | $90 |
| 2026-04-14 | init | Raymond James | — → Strong Buy | $80 |
| 2026-04-14 | main | Deutsche Bank | Buy → Buy | $88 |
| 2026-04-13 | main | Leerink Partners | Outperform → Outperform | $106 |
| 2026-04-13 | main | Jefferies | Buy → Buy | $85 |
| 2026-04-13 | main | BTIG | Buy → Buy | $98 |
| 2026-03-31 | reit | BTIG | Buy → Buy | $70 |
| 2026-03-18 | main | Stifel | Buy → Buy | $92 |
| 2026-03-16 | reit | BTIG | Buy → Buy | $70 |
| 2026-02-20 | main | Wells Fargo | Overweight → Overweight | $50 |
| 2026-02-20 | reit | BTIG | Buy → Buy | $70 |
| 2026-01-16 | reit | BTIG | Buy → Buy | $70 |
| 2025-12-18 | init | Mizuho | — → Outperform | $53 |
| 2025-12-17 | init | Citigroup | — → Buy | $64 |
| 2025-12-01 | up | Jones Trading | Hold → Buy | $64 |
| 2025-09-26 | init | Deutsche Bank | — → Buy | $43 |
| 2025-09-16 | reit | BTIG | Buy → Buy | $70 |
- SYRE stock jumps more than 70% in a month: What is driving this rally? - MSN Sun, 26 Apr 2026 19
- How Investors May Respond To Spyre Therapeutics (SYRE) Upsized Equity Raise After Positive SPY001 Phase 2 Data - simplywall.st Sun, 26 Apr 2026 20
- (SYRE) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily Sun, 26 Apr 2026 14
- Monday brings new ulcerative colitis trial results from Spyre - Stock Titan Fri, 10 Apr 2026 07
- Billionaire Joe Edelman’s 5 Stock Picks with Huge Upside Potential - Insider Monkey Sun, 26 Apr 2026 21
- Spyre Therapeutics Flies On Takeda-Rivaling Ulcerative Colitis Results - Investor's Business Daily Mon, 13 Apr 2026 07
- $SYRE stock is up 25% today. Here's what we see in our data. - Quiver Quantitative Mon, 13 Apr 2026 14
- SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits Mon, 13 Apr 2026 20
- Here’s What Raymond James Says About Spyre Therapeutics Inc (SYRE) - Yahoo Finance hu, 23 Apr 2026 09
- Perceptive (NASDAQ: SYRE) reports 4.32M shares, 5.0% stake - Stock Titan Wed, 22 Apr 2026 20
- A Look At Spyre Therapeutics (SYRE) Valuation After Positive SKYLINE Data And Strong Buy Analyst Initiation - simplywall.st Fri, 24 Apr 2026 12
- Spyre Therapeutics (SYRE) holders keep near-10% stake, agree to 60-day lock-up - Stock Titan Mon, 20 Apr 2026 22
- SYRE stock marks best session in about 3 years — here’s why - MSN Sat, 25 Apr 2026 20
- Spyre Therapeutics (SYRE) CEO sells 15,000 shares in planned trades - Stock Titan Fri, 03 Apr 2026 07
- Spyre pulls in $463.5M after underwriters take all extra shares - Stock Titan hu, 16 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
-100.00%
|
0.89
-61.96%
|
2.33
|
| Operating Revenue |
|
0.00
|
0.00
-100.00%
|
0.89
-61.96%
|
2.33
|
| Operating Expense |
|
219.56
+5.27%
|
208.57
+61.12%
|
129.45
+48.61%
|
87.11
|
| Research And Development |
|
171.65
+5.44%
|
162.79
+81.88%
|
89.50
+52.79%
|
58.58
|
| Selling General And Administration |
|
47.91
+4.66%
|
45.78
+14.59%
|
39.95
+40.01%
|
28.53
|
| General And Administrative Expense |
|
47.91
+4.66%
|
45.78
+14.59%
|
39.95
+40.01%
|
28.53
|
| Other Gand A |
|
47.91
+4.66%
|
45.78
+14.59%
|
39.95
+40.01%
|
28.53
|
| Total Expenses |
|
219.56
+5.27%
|
208.57
+61.12%
|
129.45
+48.61%
|
87.11
|
| Operating Income |
|
-219.56
-5.27%
|
-208.57
-62.23%
|
-128.56
-51.64%
|
-84.78
|
| Total Operating Income As Reported |
|
-209.56
-0.48%
|
-208.57
+13.92%
|
-242.30
-185.80%
|
-84.78
|
| EBITDA |
|
-219.56
-5.27%
|
-208.57
-63.17%
|
-127.82
-54.34%
|
-82.82
|
| Normalized EBITDA |
|
-229.56
-10.07%
|
-208.57
-400.32%
|
69.45
+183.86%
|
-82.82
|
| Reconciled Depreciation |
|
0.00
|
0.00
-100.00%
|
0.74
-62.12%
|
1.96
|
| EBIT |
|
-219.56
-5.27%
|
-208.57
-62.23%
|
-128.56
-51.64%
|
-84.78
|
| Total Unusual Items |
|
10.00
|
0.00
+100.00%
|
-197.27
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
10.00
|
0.00
+100.00%
|
-197.27
|
0.00
|
| Special Income Charges |
|
10.00
|
0.00
+100.00%
|
-113.74
|
0.00
|
| Other Special Charges |
|
—
|
—
|
130.19
|
—
|
| Net Income |
|
-155.20
+25.39%
|
-208.02
+38.60%
|
-338.79
-304.21%
|
-83.81
|
| Pretax Income |
|
-155.22
+25.36%
|
-207.97
+38.62%
|
-338.82
-303.59%
|
-83.95
|
| Net Non Operating Interest Income Expense |
|
24.89
+16.77%
|
21.31
+246.71%
|
6.15
+634.41%
|
0.84
|
| Net Interest Income |
|
24.89
+16.77%
|
21.31
+246.71%
|
6.15
+634.41%
|
0.84
|
| Interest Income Non Operating |
|
24.89
+16.77%
|
21.31
+246.71%
|
6.15
+634.41%
|
0.84
|
| Interest Income |
|
24.89
+16.77%
|
21.31
+246.71%
|
6.15
+634.41%
|
0.84
|
| Other Income Expense |
|
39.46
+290.50%
|
-20.71
+90.43%
|
-216.40
-3091314.29%
|
-0.01
|
| Other Non Operating Income Expenses |
|
29.46
+242.22%
|
-20.71
-8.27%
|
-19.13
-273185.71%
|
-0.01
|
| Gain On Sale Of Security |
|
—
|
—
|
-83.53
|
—
|
| Tax Provision |
|
-0.01
-129.41%
|
0.05
+296.15%
|
-0.03
+80.88%
|
-0.14
|
| Tax Rate For Calcs |
|
0.00
-99.95%
|
0.00
+272627.27%
|
0.00
-95.25%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
+100.00%
|
-0.02
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-155.20
+25.39%
|
-208.02
+38.60%
|
-338.79
-304.21%
|
-83.81
|
| Net Income From Continuing Operation Net Minority Interest |
|
-155.20
+25.39%
|
-208.02
+38.60%
|
-338.79
-304.21%
|
-83.81
|
| Net Income From Continuing And Discontinued Operation |
|
-155.20
+25.39%
|
-208.02
+38.60%
|
-338.79
-304.21%
|
-83.81
|
| Net Income Continuous Operations |
|
-155.20
+25.39%
|
-208.02
+38.60%
|
-338.79
-304.21%
|
-83.81
|
| Normalized Income |
|
-165.20
+20.58%
|
-208.02
-46.97%
|
-141.54
-68.87%
|
-83.81
|
| Net Income Common Stockholders |
|
-155.20
+25.39%
|
-208.02
+38.60%
|
-338.79
-304.21%
|
-83.81
|
| Diluted EPS |
|
-1.98
+37.74%
|
-3.18
+76.89%
|
-13.76
+44.40%
|
-24.75
|
| Basic EPS |
|
-1.98
+37.74%
|
-3.18
+76.89%
|
-13.76
+44.40%
|
-24.75
|
| Basic Average Shares |
|
64.06
+36.21%
|
47.03
+581.85%
|
6.90
+104.59%
|
3.37
|
| Diluted Average Shares |
|
64.06
+36.21%
|
47.03
+581.85%
|
6.90
+104.59%
|
3.37
|
| Diluted NI Availto Com Stockholders |
|
-155.20
+25.39%
|
-208.02
+38.60%
|
-338.79
-304.21%
|
-83.81
|
| Gain On Sale Of PPE |
|
10.00
|
0.00
-100.00%
|
16.45
|
0.00
|
| Preferred Stock Dividends |
|
—
|
58.46
-76.03%
|
243.91
|
—
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
341.86
|
| Current Assets |
|
341.53
|
| Cash Cash Equivalents And Short Term Investments |
|
339.28
|
| Cash And Cash Equivalents |
|
188.89
|
| Other Short Term Investments |
|
150.38
|
| Receivables |
|
0.00
|
| Other Receivables |
|
—
|
| Prepaid Assets |
|
—
|
| Other Current Assets |
|
2.25
|
| Total Non Current Assets |
|
0.33
|
| Net PPE |
|
0.00
|
| Gross PPE |
|
0.00
|
| Accumulated Depreciation |
|
0.00
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
0.00
|
| Other Properties |
|
—
|
| Leases |
|
0.00
|
| Other Non Current Assets |
|
0.33
|
| Total Liabilities Net Minority Interest |
|
157.84
|
| Current Liabilities |
|
31.98
|
| Payables And Accrued Expenses |
|
26.05
|
| Payables |
|
17.48
|
| Accounts Payable |
|
0.90
|
| Current Accrued Expenses |
|
8.57
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
4.05
|
| Current Debt And Capital Lease Obligation |
|
—
|
| Current Capital Lease Obligation |
|
0.00
|
| Current Deferred Liabilities |
|
0.00
|
| Current Deferred Revenue |
|
0.00
|
| Other Current Liabilities |
|
1.88
|
| Total Non Current Liabilities Net Minority Interest |
|
125.86
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
|
| Long Term Capital Lease Obligation |
|
0.00
|
| Non Current Deferred Liabilities |
|
0.00
|
| Non Current Deferred Revenue |
|
0.00
|
| Other Non Current Liabilities |
|
41.31
|
| Preferred Securities Outside Stock Equity |
|
84.56
|
| Stockholders Equity |
|
184.02
|
| Common Stock Equity |
|
-0.91
|
| Capital Stock |
|
184.94
|
| Common Stock |
|
0.01
|
| Preferred Stock |
|
184.93
|
| Share Issued |
|
36.06
|
| Ordinary Shares Number |
|
36.06
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
763.19
|
| Retained Earnings |
|
-764.41
|
| Gains Losses Not Affecting Retained Earnings |
|
0.30
|
| Other Equity Adjustments |
|
0.30
|
| Total Equity Gross Minority Interest |
|
184.02
|
| Total Capitalization |
|
184.02
|
| Working Capital |
|
309.55
|
| Invested Capital |
|
-0.91
|
| Total Debt |
|
0.00
|
| Capital Lease Obligations |
|
0.00
|
| Net Tangible Assets |
|
184.02
|
| Tangible Book Value |
|
-0.91
|
| Dueto Related Parties Current |
|
16.58
|
| Preferred Stock Equity |
|
184.93
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-169.25
-7.52%
|
-157.41
-57.55%
|
-99.91
-24.66%
|
-80.14
|
| Cash Flow From Continuing Operating Activities |
|
-169.25
-7.52%
|
-157.41
-57.55%
|
-99.91
-24.66%
|
-80.14
|
| Net Income From Continuing Operations |
|
-155.20
+25.39%
|
-208.02
+38.60%
|
-338.79
-304.21%
|
-83.81
|
| Depreciation Amortization Depletion |
|
0.00
|
0.00
-100.00%
|
0.74
-62.12%
|
1.96
|
| Depreciation |
|
0.00
|
0.00
-100.00%
|
0.74
-62.12%
|
1.96
|
| Depreciation And Amortization |
|
0.00
|
0.00
-100.00%
|
0.74
-62.12%
|
1.96
|
| Other Non Cash Items |
|
-29.77
-245.71%
|
20.43
+6.29%
|
19.22
+4411.97%
|
0.43
|
| Stock Based Compensation |
|
37.61
-16.10%
|
44.83
+74.62%
|
25.68
+261.06%
|
7.11
|
| Asset Impairment Charge |
|
0.00
|
0.00
-100.00%
|
2.58
|
0.00
|
| Operating Gains Losses |
|
-10.00
|
—
|
198.18
+46204.67%
|
0.43
|
| Gain Loss On Investment Securities |
|
—
|
—
|
83.53
+19416.36%
|
0.43
|
| Gain Loss On Sale Of PPE |
|
-10.00
|
0.00
-100.00%
|
114.65
|
0.00
|
| Change In Working Capital |
|
-5.93
-30.88%
|
-4.53
+12.91%
|
-5.21
+5.40%
|
-5.50
|
| Change In Receivables |
|
0.00
|
0.00
-100.00%
|
0.38
-14.77%
|
0.44
|
| Change In Prepaid Assets |
|
-12.82
-337.21%
|
-2.93
-190.35%
|
3.25
+383.65%
|
-1.14
|
| Change In Payables And Accrued Expense |
|
6.88
+529.78%
|
-1.60
+77.36%
|
-7.08
-103.07%
|
-3.48
|
| Change In Accrued Expense |
|
-0.76
-105.23%
|
14.61
+398.69%
|
-4.89
-480.19%
|
-0.84
|
| Change In Payable |
|
7.65
+147.18%
|
-16.21
-642.26%
|
-2.18
+17.30%
|
-2.64
|
| Change In Account Payable |
|
7.65
+147.18%
|
-16.21
-642.26%
|
-2.18
+17.30%
|
-2.64
|
| Change In Other Working Capital |
|
—
|
—
|
0.57
+165.34%
|
-0.88
|
| Change In Other Current Liabilities |
|
0.00
|
0.00
+100.00%
|
-2.33
-434.71%
|
-0.43
|
| Investing Cash Flow |
|
-143.47
+59.39%
|
-353.29
-225.93%
|
-108.39
-290.14%
|
57.01
|
| Cash Flow From Continuing Investing Activities |
|
-143.47
+59.39%
|
-353.29
-225.93%
|
-108.39
-290.14%
|
57.01
|
| Net PPE Purchase And Sale |
|
0.00
|
0.00
-100.00%
|
0.47
+1350.00%
|
-0.04
|
| Purchase Of PPE |
|
—
|
0.00
|
0.00
+100.00%
|
-0.04
|
| Sale Of PPE |
|
0.00
|
0.00
-100.00%
|
0.47
|
0.00
|
| Capital Expenditure |
|
—
|
—
|
—
|
-0.04
|
| Net Investment Purchase And Sale |
|
-150.47
+57.41%
|
-353.29
-178.39%
|
-126.90
-322.46%
|
57.05
|
| Purchase Of Investment |
|
-522.21
+12.86%
|
-599.25
-259.26%
|
-166.80
-322.29%
|
-39.50
|
| Sale Of Investment |
|
371.74
+51.13%
|
245.97
+516.46%
|
39.90
-58.67%
|
96.55
|
| Net Business Purchase And Sale |
|
0.00
|
0.00
-100.00%
|
3.04
|
0.00
|
| Net Intangibles Purchase And Sale |
|
7.00
|
0.00
-100.00%
|
15.00
|
0.00
|
| Financing Cash Flow |
|
309.02
-24.79%
|
410.91
+13.80%
|
361.08
+746.05%
|
42.68
|
| Cash Flow From Continuing Financing Activities |
|
309.02
-24.79%
|
410.91
+13.80%
|
361.08
+746.05%
|
42.68
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
+100.00%
|
-0.02
+96.17%
|
-0.42
|
| Repayment Of Debt |
|
—
|
0.00
+100.00%
|
-0.02
+96.17%
|
-0.42
|
| Long Term Debt Payments |
|
—
|
0.00
+100.00%
|
-0.02
+96.17%
|
-0.42
|
| Net Long Term Debt Issuance |
|
—
|
0.00
+100.00%
|
-0.02
+96.17%
|
-0.42
|
| Net Common Stock Issuance |
|
311.13
+31.62%
|
236.38
+179.56%
|
84.56
+97.22%
|
42.87
|
| Proceeds From Stock Option Exercised |
|
3.31
-55.98%
|
7.51
+1754.57%
|
0.41
+82.43%
|
0.22
|
| Net Other Financing Charges |
|
-5.41
-194.83%
|
-1.84
+68.36%
|
-5.80
|
—
|
| Changes In Cash |
|
-3.70
+96.29%
|
-99.79
-165.32%
|
152.77
+681.77%
|
19.54
|
| Effect Of Exchange Rate Changes |
|
0.00
+100.00%
|
-0.00
-112.00%
|
0.03
+123.58%
|
-0.11
|
| Beginning Cash Position |
|
89.42
-52.74%
|
189.22
+419.59%
|
36.42
+114.46%
|
16.98
|
| End Cash Position |
|
85.72
-4.14%
|
89.42
-52.74%
|
189.22
+419.59%
|
36.42
|
| Free Cash Flow |
|
-169.25
-7.52%
|
-157.41
-57.55%
|
-99.91
-24.60%
|
-80.18
|
| Amortization Of Securities |
|
-8.09
+29.06%
|
-11.40
-391.98%
|
-2.32
-608.87%
|
-0.33
|
| Common Stock Issuance |
|
311.13
+31.62%
|
236.38
+179.56%
|
84.56
+97.22%
|
42.87
|
| Interest Received CFO |
|
2.13
+66.02%
|
1.28
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
311.13
-23.22%
|
405.23
+10.58%
|
366.47
+754.77%
|
42.87
|
| Net Preferred Stock Issuance |
|
0.00
-100.00%
|
168.85
-40.11%
|
281.92
|
0.00
|
| Preferred Stock Issuance |
|
0.00
-100.00%
|
168.85
-40.11%
|
281.92
|
0.00
|
| Sale Of Business |
|
0.00
|
0.00
-100.00%
|
3.04
|
0.00
|
| Sale Of Intangibles |
|
7.00
|
0.00
-100.00%
|
15.00
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-16 View
- 8-K2026-04-13 View
- 8-K2026-04-13 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-03-03 View
- 42026-03-03 View
- 8-K2026-02-19 View
- 10-K2026-02-19 View
- 42026-02-04 View
- 42026-01-23 View
- 42026-01-13 View
- 42026-01-13 View
- 42026-01-13 View
- 42026-01-13 View
- 8-K2026-01-12 View
- 42026-01-06 View
- 42025-12-03 View
- 42025-11-05 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|